Video: Pluristem Says Its Placental Stem Therapy Offers "Off The Shelf" Promise
This article was originally published in The Pink Sheet Daily
Executive Summary
Pluristem Therapeutics Chairman and CEO Zami Aberman explains how stem cell therapy will shape the industry, in a recent interview at the Biotech Showcase.
You may also be interested in...
Pluristem Fast Forwards Placental Cell Therapy Into US-EU Pivotal Trial
Off-the-shelf placental cell therapy for peripheral artery disease will move from Phase I to registration stage study in US and Europe in early 2017, following “positive feedback” from FDA.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.